Plain-English translation of NCT06879379 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
Multiple myeloma is a serious blood cancer where abnormal plasma cells grow uncontrollably and damage organs. After initial chemotherapy and a stem cell transplant, doctors typically give additional treatment to keep the cancer under control. This trial compares two approaches: one group will receive KPD (a three-drug combination) for 2 consolidation cycles after transplant, while the other group will skip consolidation and go directly to maintenance therapy.
Although stem cell transplants help many people with myeloma, the cancer often comes back. Doctors want to know whether giving extra rounds of this medication after transplant—before switching to long-term maintenance—helps keep the cancer away longer and improves survival compared to maintenance therapy alone.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two groups. One group will receive KPD consolidation therapy for 2 cycles after their stem cell transplant, followed by maintenance therapy; the other group will begin maintenance therapy right away. You'll have regular clinic visits for blood tests, scans, and physical exams to monitor how you're responding and to watch for any side effects. The study will track your cancer control and overall health over time.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
China